http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 16 Oct 2026 10:29:32 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Short+Sales/Tempus+AI+%28TEM%29+Mentioned+Cautiously+at+Spruce+Point/27196707.html (Updated - October 16, 2026 10:29 AM EDT) <p>Tempus AI (NASDAQ: TEM) Mentioned Cautiously at Spruce Point</p><ul><li> Spruce Point has been short the name but mentioned today that Patty Spiller removed as Chief Marketing Officer.</li></ul> http://www.streetinsider.com/Short+Sales/Tempus+AI+%28TEM%29+Mentioned+Cautiously+at+Spruce+Point/27196707.html Fri, 16 Oct 2026 10:29:32 -0400 TEM http://www.streetinsider.com/Trader+Talk/Tempus+AI+%28TEM%29+Mentioned+Cautiously+at+Spruce+Point/27196707.html (Updated - October 16, 2026 10:29 AM EDT) <p>Tempus AI (NASDAQ: TEM) Mentioned Cautiously at Spruce Point</p><ul><li> Spruce Point has been short the name but mentioned today that Patty Spiller removed as Chief Marketing Officer.</li></ul> http://www.streetinsider.com/Trader+Talk/Tempus+AI+%28TEM%29+Mentioned+Cautiously+at+Spruce+Point/27196707.html Fri, 16 Oct 2026 10:29:32 -0400 TEM http://www.streetinsider.com/Press+Releases/Tempus+to+Report+Third+Quarter+2026+Financial+Results+on+November+2/27193260.html <p> CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the third quarter ended September 30, 2026, before U.S. markets open on Monday, November 2, 2026. </p><p> The company will host a conference call and live audio webcast at 8:45 a.m ET to discuss the results and provide a business update. The call will be led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. </p><p> The live audio webcast will be accessible through the “Events” section of the <a http://www.streetinsider.com/Press+Releases/Tempus+to+Report+Third+Quarter+2026+Financial+Results+on+November+2/27193260.html Thu, 15 Oct 2026 16:01:00 -0400 TEM http://www.streetinsider.com/Business+Wire/Tempus+to+Report+Third+Quarter+2026+Financial+Results+on+November+2/27193260.html <p> CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the third quarter ended September 30, 2026, before U.S. markets open on Monday, November 2, 2026. </p><p> The company will host a conference call and live audio webcast at 8:45 a.m ET to discuss the results and provide a business update. The call will be led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. </p><p> The live audio webcast will be accessible through the “Events” section of the <a http://www.streetinsider.com/Business+Wire/Tempus+to+Report+Third+Quarter+2026+Financial+Results+on+November+2/27193260.html Thu, 15 Oct 2026 16:01:00 -0400 TEM http://www.streetinsider.com/Press+Releases/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html <p><strong>AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034</strong></p><p>NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is starting to change the way healthcare works, and the opportunity is getting harder to ignore. From spotting diseases earlier to helping doctors make better decisions, AI is finding its way into more areas of medicine. Hospitals are looking for ways to improve patient care, reduce costs and handle growing workloads, while pharmaceutical companies are turning to AI to speed up drug discovery and http://www.streetinsider.com/Press+Releases/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html Thu, 15 Oct 2026 08:45:00 -0400 AIDR AIDX IQV TEM WELL http://www.streetinsider.com/Globe+Newswire/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html <p><strong>AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034</strong></p><p>NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is starting to change the way healthcare works, and the opportunity is getting harder to ignore. From spotting diseases earlier to helping doctors make better decisions, AI is finding its way into more areas of medicine. Hospitals are looking for ways to improve patient care, reduce costs and handle growing workloads, while pharmaceutical companies are turning to AI to speed up drug discovery and http://www.streetinsider.com/Globe+Newswire/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html Thu, 15 Oct 2026 08:45:00 -0400 AIDR AIDX IQV TEM WELL http://www.streetinsider.com/Press+Releases/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html <p><strong>AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034</strong></p><p>NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is starting to change the way healthcare works, and the opportunity is getting harder to ignore. From spotting diseases earlier to helping doctors make better decisions, AI is finding its way into more areas of medicine. Hospitals are looking for ways to improve patient care, reduce costs and handle growing workloads, while pharmaceutical companies are turning to AI to speed up drug discovery and http://www.streetinsider.com/Press+Releases/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html Thu, 15 Oct 2026 08:45:00 -0400 AIDR AIDX IQV TEM WELL http://www.streetinsider.com/Globe+Newswire/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html <p><strong>AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034</strong></p><p>NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is starting to change the way healthcare works, and the opportunity is getting harder to ignore. From spotting diseases earlier to helping doctors make better decisions, AI is finding its way into more areas of medicine. Hospitals are looking for ways to improve patient care, reduce costs and handle growing workloads, while pharmaceutical companies are turning to AI to speed up drug discovery and http://www.streetinsider.com/Globe+Newswire/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html Thu, 15 Oct 2026 08:45:00 -0400 AIDR AIDX IQV TEM WELL http://www.streetinsider.com/Press+Releases/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html <p><strong>AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034</strong></p><p>NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is starting to change the way healthcare works, and the opportunity is getting harder to ignore. From spotting diseases earlier to helping doctors make better decisions, AI is finding its way into more areas of medicine. Hospitals are looking for ways to improve patient care, reduce costs and handle growing workloads, while pharmaceutical companies are turning to AI to speed up drug discovery and http://www.streetinsider.com/Press+Releases/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html Thu, 15 Oct 2026 08:45:00 -0400 AIDR AIDX IQV TEM WELL http://www.streetinsider.com/Globe+Newswire/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html <p><strong>AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034</strong></p><p>NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is starting to change the way healthcare works, and the opportunity is getting harder to ignore. From spotting diseases earlier to helping doctors make better decisions, AI is finding its way into more areas of medicine. Hospitals are looking for ways to improve patient care, reduce costs and handle growing workloads, while pharmaceutical companies are turning to AI to speed up drug discovery and http://www.streetinsider.com/Globe+Newswire/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html Thu, 15 Oct 2026 08:45:00 -0400 AIDR AIDX IQV TEM WELL http://www.streetinsider.com/Press+Releases/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html <p><strong>AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034</strong></p><p>NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is starting to change the way healthcare works, and the opportunity is getting harder to ignore. From spotting diseases earlier to helping doctors make better decisions, AI is finding its way into more areas of medicine. Hospitals are looking for ways to improve patient care, reduce costs and handle growing workloads, while pharmaceutical companies are turning to AI to speed up drug discovery and http://www.streetinsider.com/Press+Releases/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html Thu, 15 Oct 2026 08:45:00 -0400 AIDR AIDX IQV TEM WELL http://www.streetinsider.com/Globe+Newswire/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html <p><strong>AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034</strong></p><p>NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is starting to change the way healthcare works, and the opportunity is getting harder to ignore. From spotting diseases earlier to helping doctors make better decisions, AI is finding its way into more areas of medicine. Hospitals are looking for ways to improve patient care, reduce costs and handle growing workloads, while pharmaceutical companies are turning to AI to speed up drug discovery and http://www.streetinsider.com/Globe+Newswire/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html Thu, 15 Oct 2026 08:45:00 -0400 AIDR AIDX IQV TEM WELL http://www.streetinsider.com/Press+Releases/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html <p><strong>AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034</strong></p><p>NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is starting to change the way healthcare works, and the opportunity is getting harder to ignore. From spotting diseases earlier to helping doctors make better decisions, AI is finding its way into more areas of medicine. Hospitals are looking for ways to improve patient care, reduce costs and handle growing workloads, while pharmaceutical companies are turning to AI to speed up drug discovery and http://www.streetinsider.com/Press+Releases/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html Thu, 15 Oct 2026 08:45:00 -0400 AIDR AIDX IQV TEM WELL http://www.streetinsider.com/Globe+Newswire/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html <p><strong>AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034</strong></p><p>NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is starting to change the way healthcare works, and the opportunity is getting harder to ignore. From spotting diseases earlier to helping doctors make better decisions, AI is finding its way into more areas of medicine. Hospitals are looking for ways to improve patient care, reduce costs and handle growing workloads, while pharmaceutical companies are turning to AI to speed up drug discovery and http://www.streetinsider.com/Globe+Newswire/The+%241+Trillion+AI+Healthcare+Revolution%3A+A+New+Era+of+Medical+Innovation+Is+Taking+Shape/27190423.html Thu, 15 Oct 2026 08:45:00 -0400 AIDR AIDX IQV TEM WELL http://www.streetinsider.com/Corporate+News/Ambry+Genetics+launches+whole+genome+sequencing+test+for+rare+diseases/27176245.html <p>Ambry Genetics, a wholly owned subsidiary of Tempus AI (NASDAQ: TEM), has launched GenomeNext and GenomeReveal, a whole genome sequencing solution aimed at improving diagnosis for patients with rare diseases.</p><p>The offering combines whole genome sequencing, RNA analysis, and ongoing reanalysis of patient data. GenomeNext uses a pangenome reference intended to better represent human genetic diversity and improve variant detection across diverse ancestral backgrounds. GenomeReveal adds integrated RNA analysis to help interpret certain DNA findings.</p><p>The solution includes Ambry's Patient for Life program, through which the laboratory proactively reanalyzes patient data as gene-disease knowledge evolves. According to the company, its laboratory-driven reanalysis http://www.streetinsider.com/Corporate+News/Ambry+Genetics+launches+whole+genome+sequencing+test+for+rare+diseases/27176245.html Tue, 13 Oct 2026 06:02:13 -0400 TEM http://www.streetinsider.com/Hot+Corp.+News/Ambry+Genetics+launches+whole+genome+sequencing+test+for+rare+diseases/27176245.html <p>Ambry Genetics, a wholly owned subsidiary of Tempus AI (NASDAQ: TEM), has launched GenomeNext and GenomeReveal, a whole genome sequencing solution aimed at improving diagnosis for patients with rare diseases.</p><p>The offering combines whole genome sequencing, RNA analysis, and ongoing reanalysis of patient data. GenomeNext uses a pangenome reference intended to better represent human genetic diversity and improve variant detection across diverse ancestral backgrounds. GenomeReveal adds integrated RNA analysis to help interpret certain DNA findings.</p><p>The solution includes Ambry's Patient for Life program, through which the laboratory proactively reanalyzes patient data as gene-disease knowledge evolves. According to the company, its laboratory-driven reanalysis http://www.streetinsider.com/Hot+Corp.+News/Ambry+Genetics+launches+whole+genome+sequencing+test+for+rare+diseases/27176245.html Tue, 13 Oct 2026 06:02:13 -0400 TEM http://www.streetinsider.com/Press+Releases/Ambry+Genetics+Announces+GenomeNext%E2%84%A2%2C+a+Whole+Genome+Sequencing+Test+Solution+to+Improve+Diagnosis+for+Rare+Diseases/27176130.html <p> <i>New offering combines whole genome sequencing, RNA analysis and ongoing reanalysis to help address diagnostic challenges</i> </p> <p> ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Ambry Genetics, a leader in clinical genomic testing and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced the launch of <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fambrygen.com%2Fproviders%2Fgenetic-testing%2F28502%2Fclinical-genomics%2Fgenomenext-and-genomereveal&amp;esheet=54619067&amp;newsitemid=20261013424274&amp;lan=en-US&amp;anchor=GenomeNext%26%238482%3B&amp;index=1&amp;md5=a18bba71705fcd4c3435e503bfd46b02" shape="rect">GenomeNext™</a> and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fambrygen.com%2Fproviders%2Fgenetic-testing%2F28502%2Fclinical-genomics%2Fgenomenext-and-genomereveal&amp;esheet=54619067&amp;newsitemid=20261013424274&amp;lan=en-US&amp;anchor=GenomeReveal%26%238482%3B&amp;index=2&amp;md5=66082d292afd0cd574796b7236acc8f5" shape="rect">GenomeReveal™</a>, a comprehensive whole genome sequencing (WGS) solution designed to help improve diagnosis of patients with rare diseases. </p><p> Many patients and families undergo years of testing without a diagnosis, and even comprehensive genetic testing can miss or be unable to interpret disease-causing changes. GenomeNext brings http://www.streetinsider.com/Press+Releases/Ambry+Genetics+Announces+GenomeNext%E2%84%A2%2C+a+Whole+Genome+Sequencing+Test+Solution+to+Improve+Diagnosis+for+Rare+Diseases/27176130.html Tue, 13 Oct 2026 06:00:00 -0400 TEM http://www.streetinsider.com/Business+Wire/Ambry+Genetics+Announces+GenomeNext%E2%84%A2%2C+a+Whole+Genome+Sequencing+Test+Solution+to+Improve+Diagnosis+for+Rare+Diseases/27176130.html <p> <i>New offering combines whole genome sequencing, RNA analysis and ongoing reanalysis to help address diagnostic challenges</i> </p> <p> ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Ambry Genetics, a leader in clinical genomic testing and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced the launch of <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fambrygen.com%2Fproviders%2Fgenetic-testing%2F28502%2Fclinical-genomics%2Fgenomenext-and-genomereveal&amp;esheet=54619067&amp;newsitemid=20261013424274&amp;lan=en-US&amp;anchor=GenomeNext%26%238482%3B&amp;index=1&amp;md5=a18bba71705fcd4c3435e503bfd46b02" shape="rect">GenomeNext™</a> and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fambrygen.com%2Fproviders%2Fgenetic-testing%2F28502%2Fclinical-genomics%2Fgenomenext-and-genomereveal&amp;esheet=54619067&amp;newsitemid=20261013424274&amp;lan=en-US&amp;anchor=GenomeReveal%26%238482%3B&amp;index=2&amp;md5=66082d292afd0cd574796b7236acc8f5" shape="rect">GenomeReveal™</a>, a comprehensive whole genome sequencing (WGS) solution designed to help improve diagnosis of patients with rare diseases. </p><p> Many patients and families undergo years of testing without a diagnosis, and even comprehensive genetic testing can miss or be unable to interpret disease-causing changes. GenomeNext brings http://www.streetinsider.com/Business+Wire/Ambry+Genetics+Announces+GenomeNext%E2%84%A2%2C+a+Whole+Genome+Sequencing+Test+Solution+to+Improve+Diagnosis+for+Rare+Diseases/27176130.html Tue, 13 Oct 2026 06:00:00 -0400 TEM http://www.streetinsider.com/Analyst+PT+Change/Tempus+AI+Inc+%28TEM%29+PT+Raised+to+%2495+at+Canaccord/27173687.html Canaccord analyst Kyle Mikson raised the price target on Tempus AI Inc (NASDAQ: TEM) to $95.00 (from $80.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Tempus+AI+Inc+%28TEM%29+PT+Raised+to+%2495+at+Canaccord/27173687.html Mon, 12 Oct 2026 06:38:10 -0400 TEM http://www.streetinsider.com/Analyst+PT+Change/Tempus+AI+Inc+%28TEM%29+PT+Raised+to+%2485+at+Baird/27163591.html Baird analyst Catherine Schulte raised the price target on Tempus AI Inc (NASDAQ: TEM) to $85.00 (from $70.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Tempus+AI+Inc+%28TEM%29+PT+Raised+to+%2485+at+Baird/27163591.html Thu, 08 Oct 2026 07:23:49 -0400 TEM http://www.streetinsider.com/Corporate+News/Tempus+expands+collaboration+with+Moderna+and+Merck+on+cancer+therapy/27158532.html <p>Tempus (NASDAQ: TEM) announced a multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy being evaluated in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with completely resected stage IIB-IV melanoma and other cancer types.</p><p>The therapy is jointly developed by Moderna and Merck, known as MSD outside the United States and Canada. The collaboration expands on joint efforts initiated the prior year. Financial terms were not disclosed.</p><p>Under the agreement, Tempus will manage the collection and transfer of tumor tissue and blood samples required for next-generation sequencing (NGS). Subject to regulatory approvals, http://www.streetinsider.com/Corporate+News/Tempus+expands+collaboration+with+Moderna+and+Merck+on+cancer+therapy/27158532.html Wed, 07 Oct 2026 08:31:28 -0400 MRK MRNA TEM http://www.streetinsider.com/Hot+Corp.+News/Tempus+expands+collaboration+with+Moderna+and+Merck+on+cancer+therapy/27158532.html <p>Tempus (NASDAQ: TEM) announced a multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy being evaluated in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with completely resected stage IIB-IV melanoma and other cancer types.</p><p>The therapy is jointly developed by Moderna and Merck, known as MSD outside the United States and Canada. The collaboration expands on joint efforts initiated the prior year. Financial terms were not disclosed.</p><p>Under the agreement, Tempus will manage the collection and transfer of tumor tissue and blood samples required for next-generation sequencing (NGS). Subject to regulatory approvals, http://www.streetinsider.com/Hot+Corp.+News/Tempus+expands+collaboration+with+Moderna+and+Merck+on+cancer+therapy/27158532.html Wed, 07 Oct 2026 08:31:28 -0400 MRK MRNA TEM http://www.streetinsider.com/Corporate+News/Tempus+expands+collaboration+with+Moderna+and+Merck+on+cancer+therapy/27158532.html <p>Tempus (NASDAQ: TEM) announced a multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy being evaluated in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with completely resected stage IIB-IV melanoma and other cancer types.</p><p>The therapy is jointly developed by Moderna and Merck, known as MSD outside the United States and Canada. The collaboration expands on joint efforts initiated the prior year. Financial terms were not disclosed.</p><p>Under the agreement, Tempus will manage the collection and transfer of tumor tissue and blood samples required for next-generation sequencing (NGS). Subject to regulatory approvals, http://www.streetinsider.com/Corporate+News/Tempus+expands+collaboration+with+Moderna+and+Merck+on+cancer+therapy/27158532.html Wed, 07 Oct 2026 08:31:28 -0400 MRK MRNA TEM http://www.streetinsider.com/Hot+Corp.+News/Tempus+expands+collaboration+with+Moderna+and+Merck+on+cancer+therapy/27158532.html <p>Tempus (NASDAQ: TEM) announced a multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy being evaluated in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with completely resected stage IIB-IV melanoma and other cancer types.</p><p>The therapy is jointly developed by Moderna and Merck, known as MSD outside the United States and Canada. The collaboration expands on joint efforts initiated the prior year. Financial terms were not disclosed.</p><p>Under the agreement, Tempus will manage the collection and transfer of tumor tissue and blood samples required for next-generation sequencing (NGS). Subject to regulatory approvals, http://www.streetinsider.com/Hot+Corp.+News/Tempus+expands+collaboration+with+Moderna+and+Merck+on+cancer+therapy/27158532.html Wed, 07 Oct 2026 08:31:28 -0400 MRK MRNA TEM http://www.streetinsider.com/Corporate+News/Tempus+expands+collaboration+with+Moderna+and+Merck+on+cancer+therapy/27158532.html <p>Tempus (NASDAQ: TEM) announced a multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy being evaluated in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with completely resected stage IIB-IV melanoma and other cancer types.</p><p>The therapy is jointly developed by Moderna and Merck, known as MSD outside the United States and Canada. The collaboration expands on joint efforts initiated the prior year. Financial terms were not disclosed.</p><p>Under the agreement, Tempus will manage the collection and transfer of tumor tissue and blood samples required for next-generation sequencing (NGS). Subject to regulatory approvals, http://www.streetinsider.com/Corporate+News/Tempus+expands+collaboration+with+Moderna+and+Merck+on+cancer+therapy/27158532.html Wed, 07 Oct 2026 08:31:28 -0400 MRK MRNA TEM